Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

A Phase 2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion

This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).

• Patients with acute peripheral arterial occlusion of the lower limb (onset of symptoms within 14 days)
• Rutherford Class I or IIa (minimal sensory loss, no muscle weakness, audible venous flow)
• Age 18 or above
• Able to consent
• Able to follow up